New imaging method gives early indication if brain cancer therapy is effective, U-M study shows

ANN ARBOR, MI - A special type of MRI scan that measures the flow of water molecules through the brain can help doctors determine early in the course of brain cancer regimen if a patient's tumor will shrink, a new study shows.

Researchers at the University of Michigan Comprehensive Cancer Center developed the assessment, which they call a functional diffusion map. They used a magnetic resonance imaging scan that tracks the diffusion, or movement, of water through the brain and mapped the changes in diffusion from the start of therapy to three weeks later. The tumor cells block the flow of water, so as those cells die, water diffusion changes.

In the study of 20 people with malignant brain tumors, the researchers found that any change in the functional diffusion map predicted 10 weeks before traditional techniques if the tumor was responding to the chemotherapy or radiation therapy. This has potential to spare patients from weeks of a grueling treatment regimen that's not working and gives doctors the opportunity to switch patients early on to a therapy that may be more effective. Results of the study appear the week of March 28 in the early online edition of the Proceedings of the National Academy of Sciences.

Most primary brain tumors have a high mortality rate, with people surviving only 10 months after diagnosis. Typically, patients receive seven weeks of treatment, followed by a traditional MRI scan six weeks after completing therapy to determine if the tumor shrank. If the cancer did not respond to the treatment, a new approach may be tried.

Using diffusion MRI and the functional diffusion map, the U-M researchers were able to predict with 100 percent accuracy after only three weeks of treatment whether the therapy would be effective – 10 weeks before traditional methods would show a response.

“This is an important issue in terms of patient quality of life. Do you want to go through seven weeks of treatment only to find two months later that it had no effect? Using MRI tumor diffusion values to accurately predict the treatment response early on could allow some patients to switch to a more beneficial therapy and avoid the side effects of a prolonged and ineffective treatment,” said Brian Ross, Ph.D., professor of radiology and biological chemistry at the U-M Medical School and a member of the U-M Comprehensive Cancer Center.

In the study, 20 participants with brain tumors underwent diffusion MRI before beginning a new treatment involving chemotherapy, radiation therapy or a combination. Three weeks later, they had another diffusion MRI. After finishing their treatment, the participants underwent standard MRI to determine whether their tumor responded to the therapy.

After three weeks – more than two months before the final MRI scan – researchers found significant differences between the patients' scans. Some areas reflected an increase in water diffusion, suggesting tumor cell death; other areas saw a decrease in diffusion, which Ross said could be accounted for by the swelling some cells undergo before dying; and in some participants, researchers saw no change in diffusion.

“In the end, we found if the diffusion changes in any way, up or down, it correlates to a positive outcome. The magnitude or amount of change relates to the effectiveness of treatment. This indicates a different mixture of cell death pathways within the tumors. In the end, any change is good. When you think about it, if the treatment is not having an effect, the tumor will continue to grow without any change to water diffusion,” Ross said.

The researchers found that for each of the 20 patients, a change in the diffusion MRI accurately predicted the tumor's response. Researchers plan to test the technique with breast cancer and head and neck cancer.

In addition to Ross, U-M study authors are Bradford Moffat, Ph.D., assistant professor of radiology; Thomas Chenevert, Ph.D., professor of radiology; Theodore Lawrence, M.D., Ph.D., Isadore Lampe Professor and Chair of Radiation Oncology; Charles Meyer, Ph.D., professor of radiology; Timothy Johnson, Ph.D., adjunct assistant professor and assistant research scientist in biostatistics; Qian Dong, M.D., a radiology fellow; Christina Tsien, M.D., lecturer in radiation oncology; Suresh Mukherji, M.D., associate professor of radiology; Douglas Quint, M.D., professor of radiology; Stephen Gebarski, M.D., professor of radiology; Patricia Robertson, M.D., associate professor of neurology and of pediatrics and communicable diseases; Larry Junck, M.D., professor of neurology; and Alnawaz Rehemtulla, Ph.D., associate professor of environmental health sciences, radiation oncology and radiology.

Funding for the study was from the National Cancer Institute and the Charles A. Dana Foundation.

The functional diffusion map is not yet available for routine use in clinic. A turn-key workstation capable of computing a diffusion map must be developed and approved by the U.S. Food and Drug Administration. The University of Michigan holds a patent on this MRI diffusion technology and has licensed the commercialization rights to Molecular Therapeutics, a corporation seeking to bring together several related technologies to create such a workstation. Ross, Rehemtulla and Chenevert, as inventors, would stand to benefit financially should the FDA approve this system and products result.

Patients seeking more information about brain cancer can call the Cancer AnswerLine at 800-865-1125, or visit www.cancer.med.umich.edu/learn/brain.htm.

Reference: Proceedings of the National Academy of Sciences, DOI 10.1073/pnas.0501532102
Related UMHS stories:
Researchers report early results of diffusion MRI http://www.med.umich.edu/opm/newspage/2001/defmri.htm

Written by Nicole Fawcett

Published on:

2005-03-30

Terms | Privacy | Contact us | Site Map | Links

Sitemap 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61
62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91
92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121
122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151
152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181
182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211
212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241
242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271
272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301
302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331
332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361
362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391
392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421
422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451
452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481
482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511
512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541
542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571
572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601
602 603 604 605 606 607 608 609 610 611 612 613 614

This website disclaims any content found in these news releases or articles. Issuers of news releases or articles are solely responsible for the accuracy of their content. If you have any questions regarding information in these news releases, please contact the issuers of the press releases.
© Copyright @ 2005. All rights Reserved. Use of our service is protected by our Privacy policy and Terms of Service.